BREMBATI, VIVIANA
BREMBATI, VIVIANA
Dipartimento di Medicina Molecolare e Traslazionale
Alpha synuclein post translational modifications: potential targets for Parkinson’s disease therapy?
2023-01-01 Brembati, V.; Faustini, G.; Longhena, F.; Bellucci, A.
An updated reappraisal of synapsins: structure, function and role in neurological and psychiatric disorders
2021-01-01 Longhena, F.; Faustini, G.; Brembati, V.; Pizzi, M.; Benfenati, F.; Bellucci, A.
Changes in α-Synuclein Posttranslational Modifications in an AAV-Based Mouse Model of Parkinson's Disease
2023-01-01 Brembati, Viviana; Faustini, Gaia; Longhena, Francesca; Outeiro, Tiago Fleming; Bellucci, Arianna
Dissecting the pathophysiology of alpha-synuclein and synapsin III interaction in conventional and patient-derived models of Parkinson’s disease
2023-02-01 Brembati, Viviana
Methylphenidate Analogues as a New Class of Potential Disease-Modifying Agents for Parkinson’s Disease: Evidence from Cell Models and Alpha-Synuclein Transgenic Mice
2022-01-01 Casiraghi, A.; Longhena, F.; Faustini, G.; Ribaudo, G.; Suigo, L.; Camacho-Hernandez, G. A.; Bono, F.; Brembati, V.; Newman, A. H.; Gianoncelli, A.; Straniero, V.; Bellucci, A.; Valoti, E.
Synapsin III gene silencing redeems alpha-synuclein transgenic mice from Parkinson's disease-like phenotype
2022-01-01 Faustini, Gaia; Longhena, Francesca; Masato, Anna; Bassareo, Valentina; Frau, Roberto; Klingstedt, Therése; Shirani, Hamid; Brembati, Viviana; Parrella, Edoardo; Vezzoli, Marika; Nilsson, K Peter R; Pizzi, Marina; Spillantini, Maria Grazia; Bubacco, Luigi; Bellucci, Arianna
The good and bad of therapeutic strategies that directly target α-synuclein
2019-01-01 Longhena, F.; Faustini, G.; Brembati, Viviana; Pizzi, M.; Bellucci, A.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Alpha synuclein post translational modifications: potential targets for Parkinson’s disease therapy? | 1-gen-2023 | Brembati, V.; Faustini, G.; Longhena, F.; Bellucci, A. | |
| An updated reappraisal of synapsins: structure, function and role in neurological and psychiatric disorders | 1-gen-2021 | Longhena, F.; Faustini, G.; Brembati, V.; Pizzi, M.; Benfenati, F.; Bellucci, A. | |
| Changes in α-Synuclein Posttranslational Modifications in an AAV-Based Mouse Model of Parkinson's Disease | 1-gen-2023 | Brembati, Viviana; Faustini, Gaia; Longhena, Francesca; Outeiro, Tiago Fleming; Bellucci, Arianna | |
| Dissecting the pathophysiology of alpha-synuclein and synapsin III interaction in conventional and patient-derived models of Parkinson’s disease | 1-feb-2023 | Brembati, Viviana | |
| Methylphenidate Analogues as a New Class of Potential Disease-Modifying Agents for Parkinson’s Disease: Evidence from Cell Models and Alpha-Synuclein Transgenic Mice | 1-gen-2022 | Casiraghi, A.; Longhena, F.; Faustini, G.; Ribaudo, G.; Suigo, L.; Camacho-Hernandez, G. A.; Bono, F.; Brembati, V.; Newman, A. H.; Gianoncelli, A.; Straniero, V.; Bellucci, A.; Valoti, E. | |
| Synapsin III gene silencing redeems alpha-synuclein transgenic mice from Parkinson's disease-like phenotype | 1-gen-2022 | Faustini, Gaia; Longhena, Francesca; Masato, Anna; Bassareo, Valentina; Frau, Roberto; Klingstedt, Therése; Shirani, Hamid; Brembati, Viviana; Parrella, Edoardo; Vezzoli, Marika; Nilsson, K Peter R; Pizzi, Marina; Spillantini, Maria Grazia; Bubacco, Luigi; Bellucci, Arianna | |
| The good and bad of therapeutic strategies that directly target α-synuclein | 1-gen-2019 | Longhena, F.; Faustini, G.; Brembati, Viviana; Pizzi, M.; Bellucci, A. |